ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0544

Targeting CD13/aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis

Eliza Pei-Suen Tsou, M.Asif Amin, Phillip Campbell, Mikel Gurrea-Rubio, Morgan Omara, Ellen Model, Pamela Palisoc, Mustafa Ali, Sirapa Vichaikul, Jonatan Hervoso, Jeffrey Ruth, Dinesh Khanna and David Fox, University of Michigan, Ann Arbor, MI

Meeting: ACR Convergence 2021

Keywords: autoimmune diseases, Fibroblasts, Dermal, fibrosis, Scleroderma, Systemic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Systemic Sclerosis & Related Disorders – Basic Science Poster (0541–0559)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Aminopeptidase N, also known as CD13, is a Zn2+-dependent membrane bound ectopeptidase widely expressed in mammalian cells including rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS), myeloid cells, and endothelial cells. CD13 exists in two forms, the membrane-binding and the MMP14 cleaved-soluble form. We previously showed that CD13 is shed from FLS. In addition, soluble (s)CD13 induces EC angiogenesis, FLS proliferation, and acute inflammatory arthritis in mice. In earlier studies we showed that sCD13 induces immune cell migration by binding to G-protein-coupled receptors. Recently we have identified bradykinin receptor B1 (B1R) as the previously unknown receptor for sCD13. We propose that CD13 is a compelling new target for scleroderma (SSc), as it induces immune cell migration and promotes fibroblast activation.

Methods: Dermal fibroblasts were isolated from skin biopsies from healthy subjects and patients with diffuse cutaneous (dc)SSc. Gene expression was analyzed by qPCR and Western blotting. sCD13 was measured using ELISA. The effects of sCD13 and B1R inhibitor on fibroblast function were analyzed using Western blotting, proliferation, migration, and gel contraction assays. To induce a myofibroblast phenotype, normal fibroblasts were incubated with TGFβ for 72 hours. The bleomycin-induced skin fibrosis mouse model was used to determine the effect of CD13 or B1R inhibition in vivo. To determine the differences between groups, Students t-test, Mann–Whitney U test, and Kruskal–Wallis test were performed. P values of less than 0.05 were considered statistically significant.

Results: CD13 knockout mice are resistant to bleomycin-induced skin fibrosis, as shown by significant reduction in skin thickness and hydroxyproline content after bleomycin injection compared to wild type mice. Dermal fibroblasts from SSc patients showed increased B1R expression and released significantly higher amount of sCD13 compared to healthy controls. In normal fibroblasts, BDKRB1 (gene encoding B1R) and MMP14 were induced by TGFβ, while ANPEP (gene encoding CD13) was downregulated. sCD13 induced pro-fibrotic gene expression, proliferation, migration, and gel contraction in SSc fibroblasts, and these effects were blocked by a B1R antagonist. Inhibition of B1R also prevented bleomycin-induced skin fibrosis in wild type mice.

Conclusion: We’ve established the pro-fibrotic properties of sCD13 in SSc fibroblasts and in an animal model of fibrosis. sCD13 exerts its pro-fibrotic effect by acting on B1R, and this in turn reinforces a myofibroblast phenotype in SSc fibroblasts. The elevated levels of B1R and sCD13 in SSc fibroblasts are mediated by TGFβ, since TGFβ increased BDKRB1 as well as MMP14 expression, which in turn cleaves CD13 into its soluble form. Targeting the sCD13-B1R axis appears to be a promising therapeutic approach for SSc.


Disclosures: E. Tsou, None; M. Amin, None; P. Campbell, None; M. Gurrea-Rubio, None; M. Omara, None; E. Model, None; P. Palisoc, None; M. Ali, None; S. Vichaikul, None; J. Hervoso, None; J. Ruth, None; D. Khanna, AbbVie, 2, Acceleron, 2, Actelion, 2, Amgen, 2, Bayer, 2, 5, Boehringer Ingelheim, 2, Bristol-Myers Squibb, 5, CiviBioPharma/Eicos Sciences, Inc, 12, Leadership/Equity position (Chief Medical Officer), Corbus, 2, CSL Behring, 2, Eicos Sciences, Inc, 11, Galapagos NV, 2, Genentech/Roche, 2, Gilead, 2, GlaxoSmithKline, 2, Horizon Therapeutics, 2, 5, Immune Tolerance Network, 5, Merck Sharp & Dohme, 2, Mitsubishi Tanabe Pharma, 2, National Institutes of Health, 5, Pfizer, 5, Sanofi-Aventis, 2, United Therapeutics, 2, Prometheus, 2, Theraly, 2, AstraZeneca, 2; D. Fox, None.

To cite this abstract in AMA style:

Tsou E, Amin M, Campbell P, Gurrea-Rubio M, Omara M, Model E, Palisoc P, Ali M, Vichaikul S, Hervoso J, Ruth J, Khanna D, Fox D. Targeting CD13/aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/targeting-cd13-aminopeptidase-n-as-a-novel-therapeutic-approach-for-scleroderma-fibrosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/targeting-cd13-aminopeptidase-n-as-a-novel-therapeutic-approach-for-scleroderma-fibrosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology